Docket no.: 03-0312 (US01)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

David K. Swanson

Serial No.: 10/727,143

Filed: December 2, 2003

For: SURGICAL METHODS AND APPARATUS FOR FORMING LESIONS IN TISSUE AND CONFIRMING WHETHER A THERAPEUTIC LESION HAS BEEN

FORMED

Group Art Unit: 3769

Confirmation No.: 5314

Examiner: ROANE, Aaron F.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR § 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. Copies of US Patents and US Patent Publications are not enclosed, pursuant to the US Patent & Trademark Office amendment to the 37 CFR § 1.98(a)(2)(i) that eliminates the requirement for a copy of each U.S. patent or U.S. patent application publication listed in an IDS in a patent application regardless of the filing date of the application. Copies of other cited references are enclosed.

Applicant would like to bring to the attention of the Examiner that U.S. Patent Application Serial Nos. 10,930,073 (US Pub. 2006-0047277, docket no. 03-0484 US01); 11/110,149 (US Pub. 2006-0195081, docket no. 04-0303 US01); 10/727,144 (US Pub. 2005-0119654, docket no. 03-0117 US01); and 11/031,629 (US Pub. 2006-0155272, docket no. 04-0453 US01); claim subject matter that is similar to the subject matter claimed in the present application.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

CERTIFICATE OF TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being transmitted to the
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below via the USPTO EFS-
Web filing system.

June 23, 2009	/NancyRushton/
Date of Deposit	Nancy Rushton

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

applica forth in before	vithin th ation file 37 CF the ma	OS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that ree months of the filing date of the application, which is not a continued prosecution ed under § 1.53(d) or (2) within three months of entry of the national stage as set R § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) illing of a first Office action after filing a request for continued examination under § no fee is required.			
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.			
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.			
	on the r	OS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance § 1.311. The fee due under 37 CFR § 1.17(p) is submitted herewith.			
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.			
fee. A	1.113 o statem	OS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue ent under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR abmitted herewith.			
		STATEMENT UNDER 37 CFR § 1.97(e):			
	Each if	tem contained in this IDS was first cited in any communication from a foreign patent			
office i	n a cou	nterpart foreign application not more than three months prior to the filing of this IDS.			
	No item contained in this IDS was cited in a communication from a foreign patent office in				
	•	foreign application, and, to the knowledge of the person signing this statement after			
Ì	-	nable inquiry, no item of information contained in this IDS was known to any			
individi	ual desi	anated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.			

Attorney Docket: 03-0312 (US01)

PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:

	A check in the amount of is enclosed for the above fee(s). Fees in the amount of \$180.00 is paid via EFS Web. Although applicant believes no fee is required, the Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Vista I Law Group LLP Deposit Account No. 50-1105.						
			Respectfully submitted, VISTA IP LAW GROUP LLP				
Dated:	June 23, 2009	Ву:	/Gary D. Lueck/ Gary D. Lueck Reg. No. 50,791	_			

Customer Number 23410 PATENT & TRADEMARK OFFICE VISTA IP LAW GROUP LLP 2040 Main Street, 9th Floor Irvine, CA 92614 Phone (949) 724-1849 Fax (949) 625-8955